Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 Registrational COMET-2 Study of AR-15512 for the Treatment of Dry Eye Disease
Stock Information for Aerie Pharmaceuticals Inc.
Loading
Please wait while we load your information from QuoteMedia.